Skip Navigation LinksHome > January 2007 - Volume 14 - Issue 1 > Multispecific myeloid defensins
Current Opinion in Hematology:
Myeloid biology

Multispecific myeloid defensins

Lehrer, Robert I

Free Access
Article Outline
Collapse Box

Author Information

David Geffen School of Medicine at UCLA, Los Angeles, California, USA

Correspondence to Robert I. Lehrer, Professor of Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA Tel: +1 310 825 5340; Fax: +1 310 206 8766; e-mail: rlehrer@mednet.ucla.edu

Disclosures: The author affirms that any opinions expressed in this review are his own, that no conflict of interest exists, and that his own research has been funded exclusively by government grants for the past decade.

Collapse Box

Abstract

Purpose of review: This review describes recent progress in our understanding of defensins and their contributions to innate immunity. Defensins are small, cysteine-rich endogenous antibiotic peptides. Human neutrophils contain large amounts of three α-defensins (HNP-1–HNP-3), and smaller amounts of a fourth, HNP-4. Monocytes and macrophages generally lack defensins, but they release messengers that induce the synthesis of β-defensins in epithelial cells.

Recent findings: In addition to their antimicrobial and immunomodulatory effects, HNP-1–HNP-3 possess antiviral and toxin-neutralizing properties. Induction of β-defensins in epithelial cells is mediated by cell-surface Toll-like receptors or cytoplasmic peptidoglycan receptors that can recognize pathogen-associated molecules. Mutations in Nod2, a cytoplasmic peptidoglycan receptor, are associated with reduced levels of intestinal α-defensins and ileal Crohn's disease. Human defensin genes show marked copy-number polymorphism. High level constitutive expression of defensins may afford protection against HIV-1 and other defensin-sensitive pathogens. Theta-defensins (cyclic octadecapeptides found in nonhuman primates) have impressive antiviral and antitoxic properties.

Summary: The multiple properties of defensins contribute to human innate immunity against bacteria, bacterial toxins, and viruses.

Abbreviations HNP: human neutrophil peptide; PMN: polymorphonuclear cell.

Back to Top | Article Outline

Introduction

Defensins are endogenous peptide antibiotics produced by certain leukocytes and many epithelial cells. Their antimicrobial, toxin-neutralizing, antiviral and immunomodulatory properties augment innate resistance to infection. Some defensins attract monocytes [1] and immature dendritic cells [2], and are immunoadjuvants [3•,4]. Others may accelerate wound repair [5,6]. Humans express two subfamilies of defensin peptides: α and β-defensins. Rhesus macaques express an additional subfamily, θ-defensins, found only in nonhuman primates [7]. Other recent reviews of defensins are available [3•,7,8••,9,10•,11••].

Back to Top | Article Outline

History

We can briefly summarize the first billion years of defensin history as follows. Plants [12,13•], fungi [14••] and various invertebrates [15] contain cysteine-rich antimicrobial peptides that are also called defensins. Plectasin, a recently described fungal defensin, shows high sequence homology to defensin peptides of dragonflies and other primitive insects [14••], consistent with descent from a common precursor. If this interpretation is correct, ancestral defensin genes existed before the fungal and insect lineages diverged (i.e., over a billion years ago). Alpha and β-defensins evolved from a common ancestral gene [16] and θ-defensin genes are modified α-defensin genes [17]. Alpha-defensins exist only in primates and glires (rodents and rabbits), relative latecomers to the planet. Beta-defensins exist in birds [18,19], reptiles [20,21] and bony fish [22]. Alpha/β/θ-defensins and plant/fungal/insect defensins share many structural features and activities. Peptides resembling β-defensins exist in horseshoe crabs [23] and sea anemones [24], but their relationship to the aforementioned defensins is uncertain.

Cysteine-rich antimicrobial peptides were noted in rabbit neutrophils (polymorphonuclear cells; PMNs) over 40 years ago [25,26]. Their human homologues were described 20 years later [27]. Neutrophils of cattle and chickens contain multiple β-defensins and no α-defensins. Neutrophils of mice, sheep and pigs lack defensins completely, but contain one or more cathelicidin peptides [28••]. Humans lost their ability to produce θ-defensin peptides as the result of a mutation that occurred approximately 7.5 million years ago [17].

Back to Top | Article Outline

Structure

Alpha, β and θ-defensins possess three intramolecular cystine disulfide bonds and have largely β-sheet structures. Beyond those shared features, defensin peptides have quite variable sequences. When recently duplicated mammalian defensin genes were examined, nonsynonymous (amino-acid-altering) substitutions exceeded synonymous substitutions in the mature defensin region [29]. Of the 29–35 amino acid residues in an α-defensin molecule, only nine are highly conserved between species: six cysteines, one glycine, one arginine and one glutamic acid. The arginine and glutamic acid residues form a salt bridge [30] that enhances resistance to degradation by neutrophil elastase [31]. A recent study [32] compared correctly folded hBD-3 (i.e., with its cysteines paired in a 1: 5, 2: 4, 3: 6 pattern) with aberrantly folded hBD-3 variants. The peptides differed in their chemotactic activity for monocytes but exerted similar antimicrobial activity against Escherichia coli. The authors concluded that disulfide bond pairing in hBD-3 was fully dispensable for its antimicrobial function. Another study [33], involving additional organisms and different assay conditions, reached a similar conclusion. Because the net charge of hBD-3 (+11) greatly exceeds that of other human defensins the dispensability of disulfide bonds for antimicrobial activity may not apply to the other defensins family members.

Back to Top | Article Outline

Antimicrobial properties

A recent study concluded that membrane depolarization contributed to the rapid killing of many bacteria by human defensins, and that additional activities, such as activation of cell-wall lytic enzymes, affected organisms such as staphylococci [10•]. Indirect actions of defensins influenced outcome when newborn piglets were challenged with Bordetella pertussis, the whooping cough organism. Piglets receiving intrapulmonary porcine β-defensin-2 were protected, even though the peptide lacked in-vitro activity against B. pertussis [34].

Back to Top | Article Outline

Antiviral properties

Human neutrophil peptides (HNPs) 1–3 were reported to inactivate herpes simplex, cytomegalovirus, influenza A, and vesicular stomatitis virus over 20 years ago [35] and were reported to inactivate HIV-1 in 1993 [36]. These reports received little attention until HNPs 1–3 were linked to a soluble and noncytotoxic anti-HIV-1 principle called ‘CAF’, supposedly secreted by the CD8(+) T-lymphocytes of untreated, clinically stable HIV-1-infected individuals [37]. After considerable controversy [38,39], the HNP/CAF identity was recanted. This was not because HNPs 1–3 lacked anti-HIV-1 activity, or because the cultured CD8(+) T-cells did not contain HNPs 1–3. Instead, the reinterpretation resulted from the observation that HNPs 1–3 found in the T-lymphocytes of these individuals were synthesized by other cells in the feeder layers. Which cells had contributed their defensins in these in-vitro experiments was not determined. Others have shown that natural killer cells and γδ-T-cells synthesize HNPs 1–3 [40], and that HNPs 1–3 inactivate extracellular HIV-1 virions and inhibit one or more steps subsequent to reverse transcription and viral integration [41•].

HNPs 1–3 have a lectin-like ability to bind viral and cell-surface glycoproteins, including gp120 and CD4 [42]. It is unclear if this property contributes to anti-HIV activity, but it may concentrate HNPs 1–3 at the virus–target cell receptor interface and enable defensins to accompany virions that enter the host cell. Retrocyclins and other θ-defensins are lectins [43] that inhibit HIV-1 entry [44,45] by binding the second heptad repeat domain (HR2) of gp41 and preventing 6-helix bundle formation [46•].

HNPs and retrocyclins also block infection by type 2 herpes simplex viruses (HSV-2). Retrocyclin-2 prevented HSV-2 attachment, whereas HNPs 1–3 acted at postbinding steps [47]. HNPs 1–3 (and HD-5) protected HeLa cells from papillomaviruses, but human β-defensins hBD-1 and hBD-2 showed little or no activity [48]. Papillomaviruses enter cells via a clathrin-dependent endocytic pathway. Neither HNP-1 nor HD-5 prevented endocytosis of papillomavirus, but both kept the virions from exiting the endocytic vesicles and entering target cells. A similar mechanism allows θ-defensins and HBD-3 to block entry of influenza A virions [49•].

The antiviral activity of α-defensins is not restricted to enveloped viruses, since HNP-1 (and hBD-1) also protects against infection by adenovirus [50,51], which also enters cells by endocytosis in clathrin-coated vesicles [52]. A review of the antiviral properties of defensins that centers on HIV-1 is available [53•].

Back to Top | Article Outline

Ancillary properties

Certain defensins enhance adaptive immune responses in mice [54,55]. More recently, α-defensins were shown to inactivate several potent bacterial exotoxins, including those released by Bacillus anthracis and Corynebacterium diphtheriae. The lethal toxin of B. anthracis contains two proteins: lethal factor and protective antigen. Lethal factor is a substrate-specific, zinc-metalloprotease that cleaves mitogen-activated protein kinase kinases. Protective antigen enables lethal factor to enter cells, where its enzymatic properties disrupt key transduction pathways. HNPs 1–3 inhibited lethal factor's enzymatic activity noncompetitively, prevented cytotoxicity in murine macrophages treated with lethal toxin, and protected mice from an otherwise fatal dose of this toxin [56••]. Theta-defensins also inactivated lethal factor and protected murine macrophages from toxin-induced cytotoxicity. Micromolar θ-defensin concentrations killed vegetative B. anthracis cells and prevented anthrax spores from germinating [57].

HNP-1 inhibits diphtheria toxin and exotoxin A of Pseudomonas aeruginosa, Both toxins are members of the mono-ADP-ribosyltransferase enzyme family [58•] that irreversibly inactivate elongation factor-2, an essential host cell protein. HNPs 1–3 also inactivate cholesterol-dependent cytolysins, exotoxins produced by many Gram-positive bacteria (W. Wang, R.I Lehrer, unpublished observation).

Back to Top | Article Outline

Defensin expression

Some defensins (e.g., HNPs 1–3 and hBD-1) are expressed constitutively, and others are induced via protein receptors on the cell surface or in the cytoplasm that recognize pathogen-associated molecular patterns. The 10 human cell surface Toll-like receptors (TLRs) include TLR2, which senses peptidoglycan, lipopeptides, and lipoproteins; TLR3, which senses double-stranded viral RNA; TLR4, which senses lipopolysaccharide, and TLR5, which binds bacterial flagellins [59]. TLRs mediate increased defensin expression via pathways that cause nuclear localization of NF-κB and activate mitogen activated protein kinase [59].

Adults produce approximately 2 × 109 neutrophils/kg body weight/day, and since each 2 × 109 PMNs contains approximately 10 mg of HNPs 1–3, the baseline production of HNPs 1–3 is about 10 mg/kg/day [60]. What happens to these peptides when neutrophils die is unknown. Many neutrophils enter the mouth by traversing gingival crevices, and crevicular fluid contains high concentrations of HNPs 1–3 [61] that may augment periodontal defenses [62].

Exposing monocytes and lymphocytes to microbe-derived molecules stimulates epidermal expression of hBD-1–hBD-3 by different pathways [63]. hBD-3 expression is governed by the epidermal growth factor receptor, which also enhances hBD-3 expression after sterile wounding [64].

NOD2 (nucleotide-binding oligomerization domain protein 2) is a cytosolic sensor-protein that recognizes muramyl dipeptide, a building block of bacterial cell walls. Activation of NOD2 by muramyl dipeptide induces hBD-2 expression in human embryonic kidney cells, via a process requiring AP-1 and NF-κB [65•]. Primary keratinocytes express NOD2 and respond to muramyl dipeptide by releasing hBD-2 [65•]. NOD2 is expressed abundantly in human monocytes and intestinal Paneth cells [66]. Many patients with ileal Crohn's disease have a mutated NOD2 gene [67], and their intestinal Paneth cells show reduced expression of intestinal α-defensins [68•]. NOD2 mutations may predispose to Crohn's disease by failing to sense certain intestinal bacteria, or by failing to link recognition to a response that includes α-defensin expression. Crohn's disease in other sites may be associated with impaired induction of colonic β-defensins, hBD-2 and hBD-3 [65•,69].

Back to Top | Article Outline

Mononuclear cells

Lipopolysaccharide-stimulated human monocytes and uterine macrophages release bioactive IL-1β, which induces hBD-2 synthesis in uterine epithelial cells [70]. Studies with human lung epithelial and macrophage-like cell lines led to similar conclusions [71]. Beta-chemokines (MIP-1α, MIP-1β, and RANTES) cause PMNs to degranulate and release HNPs 1–3 [72]. High levels of these chemokines were found in sera from nine Taiwanese women who remained uninfected despite multiple sexual contacts with HIV-1-infected partners. Their blood contained increased numbers of partially degranulated PMNs that had released their α-defensins [72]. In nine Italian women who remained uninfected despite high-level exposure to HIV-1, constitutive α-defensin production in their peripheral CD8(+) T cells was 10-fold higher than that in healthy, uninfected controls [73].

Alpha-defensins are highly expressed by human natural killer cells [40,74] and exposing these cells to bacterial antigens [e.g., flagellin and Klebsiella pneumoniae outer membrane protein A (OmpA)] stimulated both defensin synthesis and release [75].

Back to Top | Article Outline

Defensin genes

Many defensin genes cluster within a two-megabase region of human chromosome 8p23.1 whose segmental duplications and anomalies make it difficult to associate disease entities to defensin polymorphisms [76]. Nevertheless, asthma and atopy were reported to be associated with DefB1 polymorphisms [77,78] and two different β-defensin-1 polymorphisms were associated with chronic obstructive pulmonary disease phenotypes in Japanese [79] and Chinese [80] populations, but not in a Caucasian population [81].

Human DEFA1 and DEFA3 genes occur in cassettes of 19 kb tandem repeats that vary from four to 11 per diploid genome. Approximately 10% of people tested lack DEFA3 genes completely, and their neutrophils contain only HNP-1 and HNP-2 [82•]. The β-defensin locus on 8p23 contains genes encoding hBD-1, hBD-2, hBD-3 and hBD-4. Three of these genes are highly polymorphic in European populations [83]. Underlying causes for this complexity were recently reviewed [84••,85]. A genomics approach based on hidden Markov models identified 28 new human β-defensin genes, most of which appeared to be transcribed. These new genes clustered at four loci: 8p22 (11 genes and one pseudogene), 6p12 (five genes), 20q11.1 (10 genes) and 20p13 (five genes) [86].

Several β-defensin like genes exist in zebrafish and are constitutively expressed in the gills, gonad, gut, kidney, muscle, skin and spleen [22]. Chickens have at least 13 different β-defensin genes, with seven (gallinacins 1–7) expressed in bone marrow and the respiratory tract, and the others primarily in the liver and urogenital tract [18].

Human α-defensin [82•,87•,88] and β-defensin genes show marked copy number polymorphism. In two studies that examined 138 persons, the combined copy numbers of genes encoding HNP-1 (DEFA1) and HNP-3 (DEFA3) ranged from four to 14 per diploid genome [82•,87•]. The DEFA3 allele was absent in approximately 10% of normal subjects. HNP-2, a 29-residue peptide, is identical to residues two to 30 of both HNP-1 and HNP-3, and is derived from one or both of these by the posttranslational removal of an N-terminal alanine from HNP-1 or an aspartic acid from HNP-3. The genes that encode hBD-3 (DEFB103A) and hBD-4 (DEFB4) varied from two to eight copies per diploid genome. Copy numbers of DEFA1/DEFA3 genes and the DEFB4 and DEFB103A genes varied independently [87•]. It is not known if variability in defensin gene copy numbers influences their abundance in neutrophils, natural killer cells and CD8(+) T-cells, and affects resistance to viral or microbial infection.

Back to Top | Article Outline

Theta defensins

These 18-residue defensins, expressed in the neutrophils of nonhuman primates, are the only known circular peptides of animal origin [89] and the smallest known carbohydrate-binding molecules (lectins) [43]. Human θ-defensin genes exist in multiple copies, and are transcribed [17,44]. The human θ-defensin genes, however, and their mRNA contain a premature stop codon mutation in the signal sequence. Retrocyclins are synthetic θ-defensin peptides based on sequences encoded in these human pseudogenes. In-vitro, retrocyclins prevented HIV-1 [44,46•], influenza A [49•] and herpes simplex viruses [47] from entering cells. Retrocyclins also killed B. anthracis, inactivated its lethal toxin, and prevented anthrax spores from germinating [57]. While many of these activities resembled those of α-defensins, the mechanisms differed in many details.

Back to Top | Article Outline

Clinical correlations

The principal myeloid α-defensins, HNPs 1–3, are expressed in largest amount in neutrophils. Consequently, neutropenia is the most commonly encountered setting associated with myeloid defensin deficiency. Since neutrophils possess and use many other antimicrobial weapons, it is difficult to assess the overall significance of defensins to their function. Synthesis of HNPs 1–3 by human natural killer cells [75,90] and CD8(+) T cells is established, but whether their ability to produce these defensins is influenced by the gene copy number polymorphism described above is uncertain. It would be worth measuring defensin gene copy numbers in individuals who appear unusually resistant to infection by defensin-sensitive viral and microbial pathogens.

Back to Top | Article Outline

Conclusion

Defensins are central components of the human innate immune system. Although their antimicrobial activities are well documented, their antitoxic and antiviral properties are just beginning to attract attention. The marked copy number polymorphism of human defensin genesis is intriguing, especially if it can ultimately help to explain why some people may be more resistant to infections than others, perhaps including HIV-1, that are caused by defensin-susceptible pathogens.

Back to Top | Article Outline

Acknowledgements

I thank the NIH for its past support of my research. I also thank those currently working to decipher the many remaining mysteries of defensins.

Back to Top | Article Outline

References and recommended reading

Back to Top | Article Outline

Papers of particular interest, published within the annual period of review, have been highlighted as:

Back to Top | Article Outline

• of special interest

Back to Top | Article Outline

•• of outstanding interest

Back to Top | Article Outline

Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 64–65).

1 Territo MC, Ganz T, Selsted ME, Lehrer R. Monocyte-chemotactic activity of defensins from human neutrophils. J Clin Invest 1989; 84:2017–2020.

2 Yang D, Chen Q, Chertov O, Oppenheim JJ. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J Leukoc Biol 2000; 68:9–14.

3• Biragyn A. Defensins: nonantibiotic use for vaccine development. Curr Protein Pept Sci 2005; 6:53–60. This is an insightful review of the immunomodulatory and immunoenhancing properties of defensins, and their potential use in vaccine development.

4 Tani K, Murphy WJ, Chertov O, et al. Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. Int Immunol 2000; 12:691–700.

5 Aarbiou J, Verhoosel RM, van Wetering S, et al. Neutrophil defensins enhance lung epithelial wound closure and mucin gene expression in vitro. Am J Respir Cell Mol Biol 2004; 30:193–201.

6 Kudriashov BA, Kondashevskaia MV, Liapina LA, et al. Effect of defensin on the process of healing of aseptic skin wound and on the permeability of blood vessels. Biull Eksp Biol Med 1990; 109:391–393.

7 Selsted ME. Theta-defensins: cyclic antimicrobial peptides produced by binary ligation of truncated alpha-defensins. Curr Protein Pept Sci 2004; 5:365–371.

8•• Ganz T. Defensins and other antimicrobial peptides: a historical perspective and an update. Comb Chem High Throughput Screen 2005; 8:209–217.

9 Lehrer RI. Primate defensins. Nat Rev Microbiol 2004; 2:727–738.

10• Sahl HG, Pag U, Bonness S, et al. Mammalian defensins: structures and mechanism of antibiotic activity. J Leukoc Biol 2005; 77:466–475.

11•• Selsted ME, Ouellette AJ. Mammalian defensins in the antimicrobial immune response. Nat Immunol 2005; 6:551–557.

12 Lay FT, Anderson MA. Defensins-components of the innate immune system in plants. Curr Protein Pept Sci 2005; 6:85–101.

13• Silverstein KA, Graham MA, Paape TD, VandenBosch KA. Genome organization of more than 300 defensin-like genes in Arabidopsis. Plant Physiol 2005; 138:600–610.

14•• Mygind PH, Fischer RL, Schnorr KM, et al. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 2005; 437:975–980.

15 Bulet P, Stocklin R, Menin L. Antimicrobial peptides: from invertebrates to vertebrates. Immunol Rev 2004; 198:169–184.

16 Liu L, Zhao C, Heng HH, Ganz T. The human beta-defensin-1 and alpha-defensins are encoded by adjacent genes: two peptide families with differing disulfide topology share a common ancestry. Genomics 1997; 43:316–320.

17 Nguyen TX, Cole AM, Lehrer RI. Evolution of primate theta-defensins: a serpentine path to a sweet tooth. Peptides 2003; 24:1647–1654.

18 Xiao Y, Hughes AL, Ando J, et al. A genome-wide screen identifies a single beta-defensin gene cluster in the chicken: implications for the origin and evolution of mammalian defensins. BMC Genomics 2004; 5:56.

19 Lynn DJ, Higgs R, Gaines S, et al. Bioinformatic discovery and initial characterisation of nine novel antimicrobial peptide genes in the chicken. Immunogenetics 2004; 56:170–177.

20 Fadel V, Bettendorff P, Herrmann T, et al. Automated NMR structure determination and disulfide bond identification of the myotoxin crotamine from Crotalus durissus terrificus. Toxicon 2005; 46:759–767.

21 Chattopadhyay S, Sinha NK, Banerjee S, et al. Small cationic protein from a marine turtle has beta-defensin-like fold and antibacterial and antiviral activity. Proteins 2006; 64:524–531.

22 Zou J, Mercier C, Koussounadis A, Secombes C. Discovery of multiple beta-defensin like homologues in teleost fish. Mol Immunol 2007; 44:638–647.

23 Saito T, Kawabata S, Shigenaga T, et al. A novel big defensin identified in horseshoe crab hemocytes: isolation, amino acid sequence, and antibacterial activity. J Biochem (Tokyo) 1995; 117:1131–1137.

24 Driscoll PC, Clore GM, Beress L, Gronenborn AM. A proton nuclear magnetic resonance study of the antihypertensive and antiviral protein BDS-I from the sea anemone Anemonia sulcata: sequential and stereospecific resonance assignment and secondary structure. Biochemistry 1989; 28:2178–2187.

25 Zeya HI, Spitznagel JK. Cationic proteins of polymorphonuclear leukocyte lysosomes II Composition, properties, and mechanism of antibacterial action. J Bacteriol 1966; 91:755–762.

26 Zeya HI, Spitznagel JK. Cationic proteins of polymorphonuclear leukocyte lysosomes I Resolution of antibacterial and enzymatic activities. J Bacteriol 1966; 91:750–754.

27 Lehrer RI, Lichtenstein AK, Ganz T. Defensins: antimicrobial and cytotoxic peptides of mammalian cells. Annu Rev Immunol 1993; 11:105–128.

28•• Zanetti M. The role of cathelicidins in the innate host defenses of mammals. Curr Issues Mol Biol 2005; 7:179–196.

29 Hughes AL. Evolutionary diversification of the mammalian defensins. Cell Mol Life Sci 1999; 56:94–103.

30 Hill CP, Yee J, Selsted ME, Eisenberg DL. Crystal structure of defensin HNP-3, an amphiphilic dimer: mechanisms of membrane permeabilization. Science 1991; 251:1481–1485.

31 Wu Z, Li X, de Leeuw E, et al. Why is the Arg5-Glu13 salt bridge conserved in mammalian alpha-defensins? J Biol Chem 2005; 280:43039–43047.

32 Wu Z, Hoover DM, Yang D, et al. Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human beta-defensin 3. Proc Natl Acad Sci USA 2003; 100:8880–8885.

33 Kluver E, Schulz-Maronde S, Scheid S, et al. Structure-activity relation of human beta-defensin 3: influence of disulfide bonds and cysteine substitution on antimicrobial activity and cytotoxicity. Biochemistry 2005; 44:9804–9816.

34 Elahi S, Buchanan RM, Attah-Poku S, et al. The host defense peptide beta-defensin 1 confers protection against Bordetella pertussis in newborn piglets. Infect Immun 2006; 74:2338–2352.

35 Daher KA, Selsted ME, Lehrer RI. Direct inactivation of viruses by human granulocyte defensins. J Virol 1986; 60:1068–1074.

36 Nakashima H, Yamamoto N, Masuda M, Fujii N. Defensins inhibit HIV replication in vitro. AIDS 1993; 7:1129.

37 Zhang L, Yu W, He T, et al. Contribution of human alpha-defensin 1,2 and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 2002; 298:995–1000.

38 Chang TL, Francois F, Mosoian A, Klotman ME. CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition. J Virol 2003; 77:6777–6784.

39 Vella C, Daniels RS. CD8+ T-cell-mediated noncytolytic suppression of human immuno-deficiency viruses. Curr Drug Targets Infect Disord 2003; 3:97–113.

40 Agerberth B, Charo J, Werr J, et al. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000; 96:3086–3093.

41• Chang TL, Vargas F J Jr, DelPortillo A, Klotman ME. Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest 2005; 115:765–773.

42 Wang W, Owen SM, Rudolph DL, et al. Activity of alpha- and theta-defensins against primary isolates of HIV-1. J Immunol 2004; 173:515–520.

43 Wang W, Cole AM, Hong T, et al. Retrocyclin, an antiretroviral theta-defensin, is a lectin. J Immunol 2003; 170:4708–4716.

44 Cole AM, Hong T, Boo LM, et al. Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc Natl Acad Sci U S A 2002; 99:1813–1818.

45 Munk C, Wei G, Yang OO, et al. The theta-defensin, retrocyclin, inhibits HIV-1 entry. AIDS Res Hum Retroviruses 2003; 19:875–881.

46• Gallo SA, Wang W, Rawat SS, et al. θ-Defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem 2006; 281:18787–18792.

47 Yasin B, Wang W, Pang M, et al. Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J Virol 2004; 78:5147–5156.

48 Buck CB, Day PM, Thompson CD, et al. Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci U S A 2006; 103:1516–1521.

49• Leikina E, Delanoe-Ayari H, Melikov K, et al. Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat Immunol 2005; 6:995–1001.

50 Bastian A, Schafer H. Human alpha-defensin 1 (HNP-1) inhibits adenoviral infection in vitro. Regul Pept 2001; 101:157–161.

51 Gropp R, Frye M, Wagner TO, Bergon JL. Epithelial defensins impair adenoviral infection: implication for adenovirus-mediated gene therapy. Hum Gene Ther 1999; 10:957–964.

52 Meier O, Greber UF. Adenovirus endocytosis. J Gene Med 2004; 6(Suppl 1):S152–S163.

53• Klotman ME, Chang TL. Defensins in innate antiviral immunity. Nat Rev Immunol 2006; 6:447–456.

54 Oppenheim JJ, Biragyn A, Kwak LW, Yang D. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann Rheum Dis 2003; 62(Suppl 2):ii17–ii21.

55 Yang D, Biragyn A, Hoover DM, et al. Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol 2004; 22:181–215.

56•• Kim C, Gajendran N, Mittrucker HW, et al. Human alpha-defensins neutralize anthrax lethal toxin and protect against its fatal consequences. Proc Natl Acad Sci U S A 2005; 102:4830–4835.

57 Wang W, Mulakala C, Ward SC, et al. Retrocyclins kill bacilli and germinating spores of Bacillus anthracis and inactivate anthrax lethal toxin. J Biol Chem 2006; Jun 21 [Epub ahead of print].

58• Kim C, Slavinskaya Z, Merrill AR, Kaufmann SH. Human alpha-defensins neutralize toxins of the mono-ADP-ribosyltransferase family. Biochem J 2006; Jul 3 [Epub ahead of print]. This report shows that HN1-3 can neutralize a second category of microbial toxins.

59 Froy O. Regulation of mammalian defensin expression by Toll-like receptor-dependent and independent signalling pathways. Cell Microbiol 2005; 7:1387–1397.

60 Lehrer RI, Ganz T, Selsted ME. Oxygen-independent bactericidal systems Mechanisms and disorders. Hematol Oncol Clin North Am 1988; 2:159–169.

61 McKay MS, Olson E, Hesla MA, et al. Immunomagnetic recovery of human neutrophil defensins from the human gingival crevice. Oral Microbiol Immunol 1999; 14:190–193.

62 Lundy FT, Orr DF, Shaw C, et al. Detection of individual human neutrophil alpha-defensins (human neutrophil peptides 1, 2 and 3) in unfractionated gingival crevicular fluid – a MALDI-MS approach. Mol Immunol 2005; 42:575–579.

63 Sorensen OE, Thapa DR, Rosenthal A, et al. Differential regulation of beta-defensin expression in human skin by microbial stimuli. J Immunol 2005; 174:4870–4879.

64 Sorensen OE, Thapa DR, Roupe KM, et al. Injury-induced innate immune response in human skin mediated by transactivation of the epidermal growth factor receptor. J Clin Invest 2006; 116:1878–1885.

65• Voss E, Wehkamp J, Wehkamp K, et al. NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem 2006; 281:2005–2011.

66 Lala S, Ogura Y, Osborne C, et al. Crohn's disease and the NOD2 gene: a role for paneth cells. Gastroenterology 2003; 125:47–57.

67 Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005; 307:731–734.

68• Wehkamp J, Salzman NH, Porter E, et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci USA 2005; 102:18129–18134. If Paneth cells were of myeloid origin, this report would have received a second bullet point. It should be read whether or not you decided to talk to Arabidopsis.

69 Wehkamp J, Fellermann K, Stange EF. Human defensins in Crohn's disease. Chem Immunol Allergy 2005; 86:42–54.

70 Pioli PA, Weaver LK, Schaefer TM, et al. Lipopolysaccharide-induced IL-1 beta production by human uterine macrophages up-regulates uterine epithelial cell expression of human beta-defensin 2. J Immunol 2006; 176:6647–6655.

71 Tsutsumi-Ishii Y, Nagaoka I. Modulation of human beta-defensin-2 transcription in pulmonary epithelial cells by lipopolysaccharide-stimulated mononuclear phagocytes via proinflammatory cytokine production. J Immunol 2003; 170:4226–4236.

72 Jan MS, Huang YH, Shieh B, et al. CC chemokines induce neutrophils to chemotaxis, degranulation, and alpha-defensin release. J Acquir Immune Defic Syndr 2006; 41:6–16.

73 Trabattoni D, Caputo SL, Maffeis G, et al. Human alpha defensin in HIV-exposed but uninfected individuals. J Acquir Immune Defic Syndr 2004; 35:455–463.

74 Handa T, Ishihara H, Ohshima H, et al. Effects of hydrostatic pressure on matrix synthesis and matrix metalloproteinase production in the human lumbar intervertebral disc. Spine 1997; 22:1085–1091.

75 Chalifour A, Jeannin P, Gauchat JF, et al. Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers alpha-defensin production. Blood 2004; 104:1778–1783.

76 Taudien S, Galgoczy P, Huse K, et al. Polymorphic segmental duplications at 8p23.1 challenge the determination of individual defensin gene repertoires and the assembly of a contiguous human reference sequence. BMC Genomics 2004; 5:92.

77 Leung TF, Li CY, Liu EK, et al. Asthma and atopy are associated with DEFB1 polymorphisms in Chinese children. Genes Immun 2006; 7:59–64.

78 Levy H, Raby BA, Lake S, et al. Association of defensin beta-1 gene polymorphisms with asthma. J Allergy Clin Immunol 2005; 115:252–258.

79 Matsushita I, Hasegawa K, Nakata K, et al. Genetic variants of human beta-defensin-1 and chronic obstructive pulmonary disease. Biochem Biophys Res Commun 2002; 291:17–22.

80 Hu RC, Xu YJ, Zhang ZX, et al. Correlation of HDEFB1 polymorphism and susceptibility to chronic obstructive pulmonary disease in Chinese Han population. Chin Med J (Engl) 2004; 117:1637–1641.

81 Wallace AM, He JQ, Burkett KM, et al. Contribution of alpha- and beta-defensins to lung function decline and infection in smokers: an association study. Respir Res 2006; 7:76.

82• Aldred PM, Hollox EJ, Armour JA. Copy number polymorphism and expression level variation of the human alpha-defensin genes DEFA1 and DEFA3. Hum Mol Genet 2005; 14:2045–2052. Copy-number polymorphism could be important, especially if it governs the production rate of defensins in epithelial cells, NK cells or T-lymphocytes.

83 Vankeerberghen A, Scudiero O, De Boeck K, et al. Distribution of human beta-defensin polymorphisms in various control and cystic fibrosis populations. Genomics 2005; 85:574–581.

84•• Semple CA, Taylor K, Eastwood H, et al. Beta-defensin evolution: selection complexity and clues for residues of functional importance. Biochem Soc Trans 2006; 34:257–262.

85 Semple CA, Maxwell A, Gautier P, et al. The complexity of selection at the major primate beta-defensin locus. BMC Evol Biol 2005; 5:32.

86 Schutte BC, Mitros JP, Bartlett JA, et al. Discovery of five conserved beta-defensin gene clusters using a computational search strategy. Proc Natl Acad Sci U S A 2002; 99:2129–2133.

87• Linzmeier RM, Ganz T. Human defensin gene copy number polymorphisms: comprehensive analysis of independent variation in alpha- and beta-defensin regions at 8p22-p23. Genomics 2005; 86:423–430.

88 Mars WM, Patmasiriwat P, Maity T, et al. Inheritance of unequal numbers of the genes encoding the human neutrophil defensins HP-1 and HP-3. J Biol Chem 1995; 270:30371–30376.

89 Trabi M, Craik DJ. Circular proteins: no end in sight. Trends Biochem Sci 2002; 27:132–138.

90 Vermijlen D, Seynaeve C, Luo D, et al. High-density oligonucleotide array analysis reveals extensive differences between freshly isolated blood and hepatic natural killer cells. Eur J Immunol 2004; 34:2529–2540.

Cited By:

This article has been cited 29 time(s).

Journal of Biological Chemistry
Through the Looking Glass, Mechanistic Insights from Enantiomeric Human Defensins
Wei, G; de Leeuw, E; Pazgier, M; Yuan, WR; Zou, GZ; Wang, JF; Ericksen, B; Lu, WY; Lehrer, RI; Lu, WY
Journal of Biological Chemistry, 284(): 29180-29192.
10.1074/jbc.M109.018085
CrossRef
Fems Microbiology Letters
Mechanisms of action of ostrich beta-defensins against Escherichia coli
Sugiarto, H; Yu, PL
Fems Microbiology Letters, 270(2): 195-200.
10.1111/j.1574-6968.2007.00642.x
CrossRef
Inflammatory Bowel Diseases
beta-defensin production by human colonic plasma cells: A new look at plasma cells in ulcerative colitis
Rahman, A; Fahlgren, A; Sitohy, B; Baranov, V; Zirakzadeh, A; Hammarstrom, S; Danielsson, A; Hammarstrom, ML
Inflammatory Bowel Diseases, 13(7): 847-855.
10.1002/ibd.20141
CrossRef
European Journal of Clinical Investigation
Current concepts of molecular defence mechanisms operative during urinary tract infection
Weichhart, T; Haidinger, M; Horl, WH; Saemann, MD
European Journal of Clinical Investigation, 38(): 29-38.
10.1111/j.1365.2362.2008.02006.x
CrossRef
Current Opinion in Plant Biology
Micropylar pollen tube guidance and burst: adapted from defense mechanisms?
Dresselhaus, T; Marton, ML
Current Opinion in Plant Biology, 12(6): 773-780.
10.1016/j.pbi.2009.09.015
CrossRef
Medical Molecular Morphology
Role of beta-defensins in oral epithelial health and disease
Abiko, Y; Saitoh, M; Nishimura, M; Yamazaki, M; Sawamura, D; Kaku, T
Medical Molecular Morphology, 40(4): 179-184.
10.1007/s00795-007-0381-8
CrossRef
Journal of Proteomics
Human defensins as cancer biomarkers and antitumour molecules
Droin, N; Hendra, JB; Ducoroy, P; Solary, E
Journal of Proteomics, 72(6): 918-927.
10.1016/j.jprot.2009.01.002
CrossRef
Blood
Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia
Droin, N; Jacquel, A; Hendra, JB; Racoeur, C; Truntzer, C; Pecqueur, D; Benikhlef, N; Ciudad, M; Guery, L; Jooste, V; Dufour, E; Fenaux, P; Quesnel, B; Kosmider, O; Fontenay, M; Ducoroy, P; Solary, E
Blood, 115(1): 78-88.
10.1182/blood-2009-05-224352
CrossRef
Cellular Microbiology
Acid sphingomyelinase is required for efficient phago-lysosomal fusion
Schramm, M; Herz, J; Haas, A; Kronke, M; Utermohlen, O
Cellular Microbiology, 10(9): 1839-1853.
10.1111/j.1462-5822.2008.01169.x
CrossRef
Schizophrenia Bulletin
Schizophrenia Susceptibility Genes Directly Implicated in the Life Cycles of Pathogens: Cytomegalovirus, Influenza, Herpes simplex, Rubella, and Toxoplasma gondii
Carter, CJ
Schizophrenia Bulletin, 35(6): 1163-1182.
10.1093/schbul/sbn054
CrossRef
Innate Immunity
Defensins and cathelicidins in lung immunity
Tecle, T; Tripathi, S; Hartshorn, KL
Innate Immunity, 16(3): 151-159.
10.1177/1753425910365734
CrossRef
Journal of Leukocyte Biology
Human defensins and LL-37 in mucosal immunity
Doss, M; White, MR; Tecle, T; Hartshorn, KL
Journal of Leukocyte Biology, 87(1): 79-92.
10.1189/jlb.0609382
CrossRef
Microbes and Infection
Pathogenicity of environmental isolates of V-cholerae in mice
Makri, S; Purdy, AE; Bartlett, D; Fierer, J
Microbes and Infection, 9(): 1351-1358.
10.1016/j.micinf.2007.06.011
CrossRef
Current Medicinal Chemistry
Computer simulation of antimicrobial peptides
Matyus, E; Kandt, C; Tieleman, DP
Current Medicinal Chemistry, 14(): 2789-2798.

Infection and Immunity
Susceptibility to Infectious Diseases Based on Antimicrobial Peptide Production
Rivas-Santiago, B; Serrano, CJ; Enciso-Moreno, JA
Infection and Immunity, 77(): 4690-4695.
10.1128/IAI.01515-08
CrossRef
Microbiology-Sgm
The yejABEF operon of Salmonella confers resistance to antimicrobial peptides and contributes to its virulence
Eswarappa, SM; Panguluri, KK; Hensel, M; Chakravortty, D
Microbiology-Sgm, 154(): 666-678.
10.1099/mic.0.2007/011114-0
CrossRef
Peptides
Expression of human beta-defensin-2 in intratumoral vascular endothelium and in endothelial cells induced by transforming growth factor beta
Kawsar, HI; Ghosh, SK; Hirsch, SA; Koon, HB; Weinberg, A; Jin, G
Peptides, 31(2): 195-201.
10.1016/j.peptides.2009.12.008
CrossRef
Infection and Immunity
Electropositive Charge in alpha-Defensin Bactericidal Activity: Functional Effects of Lys-for-Arg Substitutions Vary with the Peptide Primary Structure
Llenado, RA; Weeks, CS; Cocco, MJ; Ouellette, AJ
Infection and Immunity, 77(): 5035-5043.
10.1128/IAI.00695-09
CrossRef
Cell Host & Microbe
Mechanism of adenovirus neutralization by human alpha-defensins
Smith, JG; Nemerow, GR
Cell Host & Microbe, 3(1): 11-19.
10.1016/j.chom.2007.12.001
CrossRef
Journal of Biological Chemistry
Elevated Expression of Paneth Cell CRS4C in Ileitis-prone SAMP1/YitFc Mice REGIONAL DISTRIBUTION, SUBCELLULAR LOCALIZATION, AND MECHANISM OF ACTION
Shanahan, MT; Vidrich, A; Shirafuji, Y; Dubois, CL; Henschen-Edman, A; Hagen, SJ; Cohn, SM; Ouellette, AJ
Journal of Biological Chemistry, 285(): 7493-7504.
10.1074/jbc.M109.083220
CrossRef
Cellular and Molecular Life Sciences
The mode of antifungal action of plant, insect and human defensins
Aerts, AM; Francois, IEJA; Cammue, BPA; Thevissen, K
Cellular and Molecular Life Sciences, 65(): 2069-2079.
10.1007/s00018-008-8035-0
CrossRef
Critical Reviews in Immunology
Neutrophil-derived defensins as modulators of innate immune function
Rehaume, LM; Hancock, REW
Critical Reviews in Immunology, 28(3): 185-200.

Gastroenterology
Defensins versus bacteria: Not just antibiotics anymore
Salzman, NH
Gastroenterology, 134(7): 2174-2177.
10.1053/j.gastro.2008.04.028
CrossRef
Antimicrobial Agents and Chemotherapy
Identification of Novel Human Immunodeficiency Virus Type 1-Inhibitory Peptides Based on the Antimicrobial Peptide Database
Wang, GS; Watson, KM; Peterkofsky, A; Buckheit, RW
Antimicrobial Agents and Chemotherapy, 54(3): 1343-1346.
10.1128/AAC.01448-09
CrossRef
Plos Pathogens
Insight into the Mechanisms of Adenovirus Capsid Disassembly from Studies of Defensin Neutralization
Smith, JG; Silvestry, M; Lindert, S; Lu, WY; Nemerow, GR; Stewart, PL
Plos Pathogens, 6(6): -.
ARTN e1000959
CrossRef
Infection and Immunity
Human defensin alpha-1 causes Trypanosoma cruzi membrane pore formation and induces DNA fragmentation, which leads to trypanosome destruction
Madison, AN; Ydeshchenko, YY; Nde, PN; Simmons, KJ; Lima, MF; Villalta, F
Infection and Immunity, 75(): 4780-4791.
10.1128/IAI.00557-07
CrossRef
European Journal of Pharmacology
The effects of alpha-defensin 1 on electrical field stimulation-induced contraction of rat bladders
Lee, SY; Do Kim, K; Park, SH; Lee, MY; Kim, HJ; Han, JH; Myung, SC
European Journal of Pharmacology, 715(): 420-423.
10.1016/j.ejphar.2013.03.032
CrossRef
Fungal Biology Reviews
Antifungal proteins: More than antimicrobials?
Hegedus, N; Marx, F
Fungal Biology Reviews, 26(4): 132-145.
10.1016/j.fbr.2012.07.002
CrossRef
AIDS
Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition
Levinson, P; Kaul, R; Kimani, J; Ngugi, E; Moses, S; MacDonald, KS; Broliden, K; Hirbod, T; the Kibera HIV Study Group,
AIDS, 23(3): 309-317.
10.1097/QAD.0b013e328321809c
PDF (257) | CrossRef
Back to Top | Article Outline
Keywords:

antiviral; defensins; retrocyclins; toxin-neutralizing

© 2007 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.